
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Buckinghamshire, UK-The pharma industry may be countercyclical, but it’s not immune to market trends. Nycomed Amersham recently postponed a partial US stock flotation of its life sciences company, ABBiotech, because of market weakness.
over 25 years ago
Industry Under Investigationover 25 years ago
Emotion - The New Brand Integratorover 25 years ago
For Love of the Gameover 25 years ago
Field of Dreamsover 25 years ago
Workshop: Access Optionsover 25 years ago
Emotion - The New Brand Integratorover 25 years ago
Rx-to-OTC: Unwanted Attentionover 25 years ago
Emotion - Biotech Renaissance Manover 25 years ago
Relocation: Coming to Americaover 25 years ago
Gathering Light





